AOD 9604 (GH Fragment 176–191): Complete Research Guide — Lipolysis Mechanism, Clinical Trial Data & White-Label Pricing (2026)

What Is AOD 9604 and Where Does It Come From?

AOD 9604 (CAS: 221231-10-3) is a synthetic hexadecapeptide derived from the C-terminal region of human growth hormone (hGH), specifically corresponding to amino acid residues 176–191 of the native hGH sequence, with a tyrosine residue added to the N-terminus to improve stability and enhance biological activity. Updated April 2026. The compound was developed by Metabolic compound Limited in Australia from foundational research conducted by Professor Fu Ng and colleagues at Monash University, who had identified in the early 1990s that the lipolytic (fat-mobilizing) activity of hGH was separable from its growth-promoting and insulin-like effects and appeared to reside primarily in the C-terminal domain (Ng et al., Mol Cell Endocrinol, 1990 — PMID: 2149308).

The “AOD” designation stands for Anti-Obesity compound — a label from the compound’s early development history that reflects the intended research application, not a description of any approved indication. AOD 9604 is not research-grade as a compound in the United States. It received a food ingredient classification from Food Standards Australia New Zealand (FSANZ) based on demonstrated safety data from multiple clinical trials — a regulatory status reflecting safety assessment for use in food products, not compound efficacy approval.

Metabolic compound advanced AOD 9604 through Phase 1, Phase 2, and Phase 2b clinical trials in the early 2000s. A 24-week efficacy study did not demonstrate statistically significant adipose tissue reduction on the primary endpoint compared to placebo, and the compound development program was not advanced to a full Phase 3 compound approval submission. The compound remains actively studied in research contexts for adipose tissue biology, cartilage repair models, and metabolic pathway investigation.

Key Characteristics

How Does AOD 9604 Work? Primary Mechanisms of Action

AOD 9604’s mechanism is defined by what it does not do as much as by what it does. Understanding this negative profile is essential for accurately characterizing its research utility relative to full-length hGH and to GHRH-pathway peptides.

Selective Beta-Adrenergic Pathway Activation in Adipose Tissue

AOD 9604 activates lipolytic signaling in adipose tissue through an interaction with the beta-adrenergic receptor system, particularly beta-3 adrenergic receptors (beta-3 AR), which are expressed predominantly in adipose tissue and mediate catecholamine-stimulated lipolysis. Published preclinical data in obese mouse models demonstrated that AOD 9604 administration increased lipolytic sensitivity and reduced adipose tissue mass, and that this effect was significantly attenuated in beta-3 AR knockout mice — confirming the involvement of beta-3 AR signaling in the compound’s mechanism of action (Heffernan et al., Endocrinology, 2001 — PMID: 11713213).

Absence of GH Receptor Binding and IGF-1 Stimulation

Full-length growth hormone exerts both lipolytic effects (via beta-adrenergic pathway activation) and somatogenic effects (via GH receptor binding, leading to IGF-1 secretion, tissue growth, and insulin resistance). AOD 9604, as the C-terminal fragment, lacks the N-terminal domain of hGH responsible for GH receptor binding. Published clinical data from six randomized controlled trials confirmed that AOD 9604 administration at all studied doses produced no significant increase in serum IGF-1 levels, no insulin resistance, and no impaired glucose tolerance — confirming the absence of GH receptor-mediated somatogenic signaling at therapeutic concentrations (Stier, Vos & Kenley, J Endocrinol Metab, 2013 — DOI: 10.4021/jem157w).

Antilipogenic Activity

In addition to promoting lipolysis (breakdown of stored triglycerides), published preclinical research documented that AOD 9604 also exerts antilipogenic activity — inhibiting the differentiation of pre-adipocytes into mature adipocytes and reducing de novo lipogenesis in adipose tissue models. This dual lipolytic and antilipogenic activity was documented in both in vitro adipocyte models and in genetically obese rodent studies (ob/ob mice and Zucker rats), providing mechanistic support for studying the compound in adipose tissue biology research (Ng et al., Mol Cell Endocrinol, 1990 — PMID: 2149308).

Cartilage and Tissue Repair Research

More recent published research has identified cartilage and connective tissue applications for AOD 9604. Intra-articular AOD 9604 injections in a collagenase-induced knee osteoarthritis rabbit model demonstrated enhanced cartilage regeneration compared to controls, with combination AOD 9604 + hyaluronic acid producing superior outcomes relative to either compound alone. This research direction extends the compound’s studied applications beyond adipose tissue metabolism into musculoskeletal repair contexts, broadening its relevance across research categories.

What Systems Has AOD 9604 Been Investigated For?

AOD 9604’s published research applications span adipose tissue metabolism, body composition research models, and cartilage biology — reflecting its selective receptor profile and the diversity of applications examined during the Metabolic compound clinical development program.

Adipose Tissue and Lipolysis Research

The foundational AOD 9604 research characterizes selective lipolytic activity in adipose tissue models. In genetically obese Zucker rats and ob/ob mice, chronic AOD 9604 administration produced measurable reductions in adipose tissue mass and increases in lipolytic enzyme activity, without the hyperglycemic and insulin-resistance effects observed with equivalent doses of full-length hGH. A 12-week randomized clinical trial cited in PMC3584306 reported subjects receiving AOD 9604 showed changes in adipose tissue parameters compared to placebo, though the 24-week primary efficacy trial did not meet statistical significance on the primary endpoint, as discussed in the human data section below.

Metabolic Pathway Research

AOD 9604’s selective receptor profile makes it a useful research tool for investigating the dissociated lipolytic versus somatogenic pathways of growth hormone biology. Published studies have used AOD 9604 alongside full-length hGH and beta-adrenergic receptor knockout models to map the specific contribution of the C-terminal lipolytic domain to metabolic outcomes independently from IGF-1-mediated growth and anabolic pathways.

Cartilage Regeneration Research

Emerging published literature documents intra-articular AOD 9604 activity in osteoarthritis models. Preclinical data in rabbit knee osteoarthritis models demonstrated dose-dependent enhancement of cartilage regeneration with AOD 9604 administration, and combination protocols with hyaluronic acid showed additive effects compared to either agent alone. This represents a mechanistically distinct application area from the compound’s original lipolysis-focused development, and has supported ongoing investigation into GH fragment activity in connective tissue repair contexts.

What Does the Human Research Data Show So Far?

AOD 9604 has a more extensive human clinical trial record than most research peptides in the metabolic category, having completed Phase 1, Phase 2, and Phase 2b trials through Metabolic compound before the development program concluded without compound approval.

Human Safety Summary

The integrated safety dataset from six randomized, double-blind, placebo-controlled trials covering approximately 900 subjects represents the most extensive human safety record for any compound in the metabolic research peptide category on the YPB platform. The critical finding across all trials was the absence of IGF-1 elevation and glucose metabolism perturbation — the two primary safety concerns associated with full-length hGH use — confirming in human subjects that the C-terminal fragment lacks the somatogenic receptor activity of the full molecule. The 24-week primary efficacy trial did not meet its primary endpoint for adipose tissue reduction, and the compound development program was not advanced. All YPB AOD 9604 products are Research Use Only and are not intended for human potential wellness benefit.

How Does AOD 9604 Compare to Other Metabolic Research Peptides?

AOD 9604 occupies a distinct position in the metabolic research peptide category: it is the only GH-derived fragment in the YPB catalog with selective adipose tissue lipolytic activity and documented absence of GH receptor binding and IGF-1 stimulation.

AOD 9604’s selective profile makes it mechanistically complementary rather than interchangeable with GHRH-pathway peptides. Researchers studying the GH axis use CJC-1295 and Sermorelin to activate endogenous GH secretion via the pituitary; AOD 9604 provides adipose tissue lipolytic pathway activation without engaging the pituitary axis at all. The Tesamorelin Research Guide covers the research-grade GHRH analog with documented visceral adipose tissue activity.

What Should Researchers Know About AOD 9604 Stability and Handling?

AOD 9604 at 1,817.1 Da is a mid-weight peptide containing an internal disulfide bridge — a structural feature that requires attention in storage and quality verification protocols.

Storage and Reconstitution Protocol

Lyophilized AOD 9604 is stable at −20°C for up to 24 months when protected from moisture, light, and oxidizing conditions. The internal disulfide bridge (between cysteine residues within the hGH 176–191 sequence) is susceptible to reduction under strongly reducing conditions and to oxidative scrambling under peroxide or air-exposed storage. Reconstitution with bacteriostatic water adjusted to mildly acidic pH is preferred. Once reconstituted, the solution should be held at 2–8°C and used within 14 days; avoid repeated freeze-thaw cycles as these can disrupt the disulfide bridge integrity.

COA Verification

At 1,817.1 Da, HPLC purity (≥98%) combined with mass spectrometry is the appropriate quality standard. MS verification should confirm the intact molecular weight corresponding to the disulfide-bridged form; the reduced (open-chain) form has a different mass and lacks the conformational constraints that determine receptor binding activity. Researchers should additionally request confirmation that the N-terminal tyrosine modification is present, as this residue is required for the enhanced stability and potency relative to the native hGH(177–191) sequence. All YPB AOD 9604 batches include lot-traceable COA documentation accessible through the COA Library.

Key Research Findings: AOD 9604 in 2026

Why Is AOD 9604 a High-Demand Research Compound?

AOD 9604 generates 27,000 monthly US searches in the research peptide metabolic category, driven by its GH-derived origin story, the clean safety record from six RCTs, and the FSANZ food ingredient classification that gives it a regulatory credibility signal absent from most research peptides.

Search Volume and Consumer Interest

AOD 9604’s search volume is sustained by a convergence of research and consumer-facing interest. Researchers studying adipose tissue metabolism approach it as a selective lipolytic research tool; practitioners familiar with the GH axis study it as a focused metabolic compound. The FSANZ food ingredient status and six-RCT safety record are frequently cited in research-facing content, contributing to high-intent search traffic that converts at above-average rates for metabolic peptide SKUs.

Publication Context and Regulatory Catalysts

PubMed indexes 100+ publications for AOD 9604 and hGH(176–191). The 2024 FDA Category 2 compounding restriction created a surge in research-grade RUO sourcing interest as practitioners shifted away from compounded supply channels — a demand catalyst that has significantly elevated search activity for research-grade AOD 9604 through 2024–2026.

Market Demand Indicators

How Can Researchers Offer AOD 9604 Under Their Own Brand?

YourPeptideBrand.com provides white-label dropship for AOD 9604 in a standalone 6mg research configuration. The compound’s six-RCT safety record, FSANZ food ingredient history, and unique GH-derived lipolytic mechanism make it a distinct SKU for white-label brands in the metabolic research category.

What White-Labeling Means

White-label operators receive pre-built RUO-compliant product pages with molecular data tables, mechanism descriptions, and COA library links. Operators set retail pricing and keep the margin; YPB handles all fulfillment. Download the full product catalog for all 60+ SKU pricing tiers.

AOD 9604 Wholesale Pricing & Margin Analysis

Use the YPB Profit Calculator to model projected monthly revenue at your target pricing and volume. AOD 9604 at Premier tier generates $80.54 gross margin per unit at $120 MSRP — a 67% margin rate in the top tier of the metabolic category. The 2024 FDA compounding restriction has increased demand for research-grade RUO supply, with white-label brands well-positioned to capture practitioners and researchers transitioning from compounded sources. 250+ white-label research brands are already live on the platform.

Who This Is For

AOD 9604 is best positioned for white-label brands targeting practitioners and researchers with specific interest in GH-derived metabolic biology — particularly those already researching GHRH-pathway compounds who want a GH-fragment compound that selectively addresses adipose tissue pathways without engaging the somatogenic axis. Brands offering CJC-1295 or Sermorelin can cross-sell AOD 9604 to the same buyer segment as a mechanistically complementary metabolic research compound.

Methodology & Data Sources

References

Frequently Asked Questions

Key Takeaways

Research Takeaways

• Selective lipolytic mechanism without GH receptor binding: AOD 9604 activates adipose tissue lipolysis via beta-3 AR interaction without binding the full GH receptor — mechanistically isolated from IGF-1 and somatogenic pathways.
• Beta-3 AR dependency confirmed in knockout model: Heffernan et al. (2001) demonstrated significantly attenuated effect in beta-3 AR knockout mice, establishing the mechanistic pathway (PMID: 11713213).
• 6 RCTs (~900 subjects): safety “indistinguishable from placebo” — no IGF-1 elevation, no insulin resistance, no glucose tolerance impairment confirmed across all six trials (Stier et al., 2013).
• Primary 24-week efficacy trial did not meet endpoint — compound development not advanced; compound is not approved as an anti-obesity compound anywhere globally.
• FSANZ food ingredient classification reflects the extensive safety data; it is a safety-based food standard classification, not a compound efficacy approval.
• Antilipogenic activity documented: Published in vitro and preclinical data demonstrates inhibition of pre-adipocyte differentiation alongside lipolytic activity in adipose tissue models.
• Disulfide bridge requires specific storage: The internal Cys-Cys bridge is essential for conformational activity and requires protection from reducing and oxidizing conditions in storage and reconstitution.

Business Takeaways

• 27,000 monthly searches at low KD — metabolic category demand sustained by GH-derived origin, six-RCT safety record, and 2024 FDA compounding restriction driving research-grade demand.
• $80.54 gross margin per unit at Premier tier (67%) — strong metabolic category margin with premium pricing supported by extensive clinical safety documentation.
• 2024 FDA Category 2 demand catalyst — compounding restrictions shifted practitioner demand toward research-grade RUO supply; white-label brands are well-positioned to capture this transition.
• Natural metabolic catalog anchor alongside CJC-1295 and Sermorelin — all three compounds target GH-related pathways through distinct mechanisms, creating a complementary three-SKU metabolic research catalog from a single traffic source.

Ready to add AOD 9604 to your research peptide catalog? Book a consultation with the YPB team to discuss metabolic category positioning and the full 60+ SKU platform.

[ypb_studies peptide=”aod-9604″]